Recent Updates — GWLL

The board of directors appointed Ming Zhou as a director on October 8, 2026. In connection with the appointment, Chief Executive Officer Shuang Liu gifted 20,000,000 shares of common stock to Ms. Zhou, representing approximately 20.2% of the issued and outstanding shares. The board now consists of four directors: Shuang Liu, Yang Lee, Hua Xie, and Ming Zhou. Goldenwell Biotech operates in the biotechnology sector.

Goldenwell Biotech, Inc. dismissed Michael Gillespie & Associates, PLLC as its independent registered public accounting firm effective September 27, 2026, following board approval. The former auditor's reports for fiscal years ended December 31, 2025 and 2024 contained no adverse opinions or qualifications but explicitly stated there is substantial doubt about the Company’s ability to continue as a going concern. There were no disagreements with the former auditor on accounting principles, financial statement disclosures, or auditing scope. The company engaged Privatco CPA Limited as its new independent registered public accountant effective September 22, 2026. Goldenwell Biotech operates in the biotechnology industry and is developing pharmaceutical products.